Comparative Pharmacology
Head-to-head clinical analysis: INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INPERSOL ZM W DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides osmotic gradient for peritoneal dialysis via hyperosmolar dextrose solution; dextrose is absorbed and metabolized, driving ultrafiltration of excess fluid and solutes across peritoneal membrane.
Provides osmotic gradient for peritoneal dialysis; glucose and icodextrin facilitate ultrafiltration and removal of waste products across the peritoneal membrane.
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, 4 exchanges daily (8 liters total per day) for continuous ambulatory peritoneal dialysis (CAPD).
2 L intraperitoneally via an indwelling peritoneal catheter, dwell time 4-6 hours, 4 exchanges per day
None Documented
None Documented
Not applicable as a continuous dialysis solution; systemic glucose half-life ~1.5-2 hours in normal physiology, but prolonged in renal impairment.
Not applicable as a traditional half-life; removal is dependent on peritoneal dialysis dwell time and membrane transport characteristics. Effective clearance half-life during dialysis is approximately 2-4 hours depending on exchange schedule.
Renal (predominantly via dialysate effluent); peritoneal dialysis removes glucose and metabolites. Less than 5% metabolized; no significant biliary or fecal excretion.
Primarily removed via peritoneal dialysis; minimal renal excretion (less than 5% unchanged). Dextrose is metabolized to CO2 and water. Biliary/fecal excretion negligible.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution